AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30712432 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic programming parameters
Number of subjects: 232982
Study 29171468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day (Group 1)
Number of subjects: 51
Study 29171468 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MB 60 mg/day (Group 2)
Number of subjects: 51
Study 25948124 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus yangxinkang tablets for 4 weeks
Number of subjects: 228
Study 25948124 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western treatment (Control)
Number of subjects: 228
Study 23170757 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Living Every Day (ALED)
Number of subjects: 280
Study 23170757 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study 21258820 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 84
Study 21258820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 84
Study 21258820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 84
Study 19088168 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 20
Study 19088168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16292334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block
Number of subjects: 18
Study 16292334 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine‐prilocaine
Number of subjects: 18
Study 16292334 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 18
Study 14585880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (800 microg)
Number of subjects: 224
Study 14585880 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (800 microg)
Number of subjects: 224
Study 14585880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes of administration
Number of subjects: 224
Study 10755498 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical vignettes
Number of subjects: 98
Study 10755498 — intervention group
Group type: COMPARATOR
Intervention: Standardized patients (SPs)
Number of subjects: 98
Study 10755498 — intervention group
Group type: COMPARATOR
Intervention: Chart abstraction
Number of subjects: 98
Study 8811737 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical crosslinking of lysine groups in vimentin
Number of subjects: 0
Study 8811737 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkages between dimers
Number of subjects: 0
Study 8811737 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular modeling of vimentin conformations
Number of subjects: 0
Study 1419813 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 61
Study 1419813 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 61
Study 6724715 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (histamine H2-receptor blocker)
Number of subjects: 5
Study 6724715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31188268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (15 mg)
Number of subjects: 25
Study 31188268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29982532 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 309
Study 29982532 — intervention group
Group type: EXPERIMENTAL
Intervention: fractional-dose IPV (fIPV)
Number of subjects: 309
Study 29982532 — intervention group
Group type: COMPARATOR
Intervention: No IPV Vaccine (Control)
Number of subjects: 309
Study 26501464 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher von Willebrand factor (vWF) activity
Number of subjects: 65
Study 26501464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower high-density lipoprotein cholesterol
Number of subjects: 65
Study 26501464 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher thromboxane B2 levels
Number of subjects: 65
Study 26501464 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NT-pro-BNP levels
Number of subjects: 65
Study 26501464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower vWF activity
Number of subjects: 65
Study 26501464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower total cholesterol
Number of subjects: 65
Study 24598526 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training (average of 45 training sessions, 5 days/week, 1 hour/day)
Number of subjects: 16
Study 24598526 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training
Number of subjects: 16
Study 21765374 — intervention group
Group type: EXPERIMENTAL
Intervention: MVR blade trocar
Number of subjects: 40
Study 21765374 — intervention group
Group type: COMPARATOR
Intervention: Beveled trocar
Number of subjects: 40
Study 21765374 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 20200239 — intervention group
Group type: EXPERIMENTAL
Intervention: Envelope genes
Number of subjects: 6
Study 20200239 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-envelope genes
Number of subjects: 6
Study 20200239 — intervention group
Group type: EXPERIMENTAL
Intervention: HVR1 sequences
Number of subjects: 6
Study 17568167 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH
Number of subjects: 52
Study 17568167 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 52
Study 15696331 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA/TRP mixture (60 g BCAA and 2 g TRP)
Number of subjects: 32
Study 15696331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11210069 — intervention group
Group type: EXPERIMENTAL
Intervention: AST > or = 800 microIU
Number of subjects: 41
Study 11210069 — intervention group
Group type: EXPERIMENTAL
Intervention: AST > or = 1,200 microIU
Number of subjects: 41
Study 11210069 — intervention group
Group type: EXPERIMENTAL
Intervention: BOP
Number of subjects: 41
Study 11210069 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative AST test result
Number of subjects: 41
Study 11210069 — intervention group
Group type: EXPERIMENTAL
Intervention: AST diagnostic criteria
Number of subjects: 41
Study 10205352 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube feeding (tube +)
Number of subjects: 129
Study 10205352 — intervention group
Group type: COMPARATOR
Intervention: Control group (tube -)
Number of subjects: 129
Study 7933535 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic plus fluconazole therapy (FLCZ group)
Number of subjects: 62
Study 7933535 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy only (antibiotic group)
Number of subjects: 62
Study 2964212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.5 mg
Number of subjects: 30
Study 2964212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29576488 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use fully disposable and patient-specific cutting guides (SU)
Number of subjects: 70
Study 29576488 — intervention group
Group type: COMPARATOR
Intervention: Traditional patient-specific cutting guides (PSI)
Number of subjects: 70
Study 29576488 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation (CI)
Number of subjects: 70
Study 28452904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin-releasing peptide (GRP) 160 pmol/kg for 4 consecutive days
Number of subjects: 10
Study 28452904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28452904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin-releasing peptide (GRP)
Number of subjects: 10
Study 26577690 — intervention group
Group type: EXPERIMENTAL
Intervention: RESTORE web-based intervention
Number of subjects: 19
Study 24252674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (500 ml administered 2-3 hours before anesthesia)
Number of subjects: 60
Study 24252674 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (500 ml administered 2-3 hours before anesthesia)
Number of subjects: 60
Study 21145284 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (50 Gy in 25 fractions over 5 weeks)
Number of subjects: 1694
Study 21145284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 5 years)
Number of subjects: 1694
Study 21145284 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (Control group)
Number of subjects: 1694
Study 18332190 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 412
Study 18332190 — intervention group
Group type: COMPARATOR
Intervention: Successful aging educational control intervention
Number of subjects: 412
Study 16525219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial-based pacing
Number of subjects: 0
Study 16525219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular-based pacing
Number of subjects: 0
Study 16525219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker therapy
Number of subjects: 0
Study 12685882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 2 weeks
Number of subjects: 114
Study 12685882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily for 4 weeks
Number of subjects: 114
Study 10574419 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg/HCTZ 12.5 mg
Number of subjects: 178
Study 10574419 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg/HCTZ 12.5 mg
Number of subjects: 178
Study 10574419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 8908379 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 8 mg once daily (q.d.)
Number of subjects: 416
Study 8908379 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg twice daily (b.i.d.)
Number of subjects: 416
Study 8908379 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 16 mg once daily (q.d.)
Number of subjects: 416
Study 8908379 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 8 mg twice daily (b.i.d.)
Number of subjects: 416
Study 8908379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 1918423 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam 2.0 mg
Number of subjects: 99
Study 6196549 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol (with PAA)
Number of subjects: 39
Study 6196549 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol (without PAA)
Number of subjects: 39
Study 6196549 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 29729848 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-gene hypoxia-related mRNA signature
Number of subjects: 130
Study 29729848 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-prostatectomy radiotherapy
Number of subjects: 130
Study 29729848 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy alone
Number of subjects: 130
Study 29729848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled cohort analysis
Number of subjects: 130
Study 29729848 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia-modifying therapy (carbogen and nicotinamide)
Number of subjects: 130
Study 26520230 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1498
Study 26520230 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1498
Study 24926075 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy plus acupuncture for 3 months
Number of subjects: 2
Study 24926075 — intervention group
Group type: COMPARATOR
Intervention: Standard combination therapy
Number of subjects: 2
Study 23160438 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular viewing with unrestricted field of view (FOV)
Number of subjects: 0
Study 23160438 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular viewing with unrestricted FOV
Number of subjects: 0
Study 23160438 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular viewing with moderately restricted FOV (40 degrees)
Number of subjects: 0
Study 23160438 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular viewing with severely restricted FOV (11.5 degrees)
Number of subjects: 0
Study 23160438 — intervention group
Group type: COMPARATOR
Intervention: Binocular viewing
Number of subjects: 0
Study 23160438 — intervention group
Group type: COMPARATOR
Intervention: Monocular viewing
Number of subjects: 0
Study 19639415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel (60, 90 or 120 mg)
Number of subjects: 108
Study 19639415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 18940558 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum injection followed by physiotherapy
Number of subjects: 8
Study 18940558 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 age/sex-matched controls)
Number of subjects: 8
Study 15975126 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization splint therapy (Group I)
Number of subjects: 40
Study 15975126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivot splint therapy (Group II)
Number of subjects: 40
Study 12689686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2.5 mg taken 30 minutes before breakfast
Number of subjects: 0
Study 12689686 — intervention group
Group type: COMPARATOR
Intervention: Ibandronate 2.5 mg taken 60 minutes before breakfast
Number of subjects: 0
Study 10628043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavage using gravity fed, home‐made unbuffered isotonic saline for 2 months
Number of subjects: 46
Study 10628043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavage
Number of subjects: 46
Study 8528172 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC infusion (1, 10, and 50 x 10(6) MPCs)
Number of subjects: 23
Study 8528172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo culture expansion of MPCs
Number of subjects: 23
Study 8528172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow examination 2 weeks post-infusion
Number of subjects: 23
Study 1835139 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus flutamide
Number of subjects: 0
Study 1835139 — intervention group
Group type: COMPARATOR
Intervention: Goserelin alone
Number of subjects: 0
Study 6753446 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoxetine (200 mg in the first week, 300 mg in the remaining weeks for 12 weeks)
Number of subjects: 59
Study 6753446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 6209476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg
Number of subjects: 9
Study 6209476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 300 mg
Number of subjects: 9
Study 6209476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6209476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2-4 micrograms/kg/min
Number of subjects: 9
Study 30029684 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance whole brain radiotherapy (HA-WBRT), 30 Gy in 10 fractions, treated in 4 centers.
Number of subjects: 215
Study 30029684 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance whole brain radiotherapy (HA-WBRT)
Number of subjects: 215
Study 30029684 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 215
Study 26831602 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 287
Study 26831602 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-water irrigation
Number of subjects: 287
Study 26831602 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 287
Study 25276626 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation along with regular medicine
Number of subjects: 48
Study 25276626 — intervention group
Group type: COMPARATOR
Intervention: Usual care (budesonide and formoterol)
Number of subjects: 48
Study 22928076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 250,000 IU
Number of subjects: 30
Study 22928076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21316541 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of nevirapine 200-mg tablet
Number of subjects: 20
Study 21316541 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of nevirapine 200-mg tablet
Number of subjects: 20
Study 19000527 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program consisting of two medical visits and a nurse visit for health education, along with two letters and two telephone calls.
Number of subjects: 79
Study 19000527 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 79
Study 15860282 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with ILM removal
Number of subjects: 12
Study 15860282 — intervention group
Group type: COMPARATOR
Intervention: Modified grid laser photocoagulation
Number of subjects: 12
Study 12442030 — intervention group
Group type: EXPERIMENTAL
Intervention: rG-CSF (5 microg/kg/dose i.v. twice a day)
Number of subjects: 28
Study 12442030 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuGM-CSF (4 microg/kg/dose i.v. twice a day)
Number of subjects: 28
Study 12442030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10865688 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based contraceptive decision aid
Number of subjects: 949
Study 7782815 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of the staff nurse and specially trained nurse facilitator in decision making
Number of subjects: 0
Study 1954661 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng compound liquor (treated group)
Number of subjects: 71
Study 1954661 — intervention group
Group type: COMPARATOR
Intervention: American ginseng liquor only (control group)
Number of subjects: 71
Study 1954661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 7466522 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker perfusion method
Number of subjects: 0
Study 7466522 — intervention group
Group type: COMPARATOR
Intervention: Simple aspiration
Number of subjects: 0
Study 7466522 — intervention group
Group type: COMPARATOR
Intervention: Simple aspiration with marker correction
Number of subjects: 0
Study 31336101 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth wheelchair skills training program
Number of subjects: 18
Study 31336101 — intervention group
Group type: COMPARATOR
Intervention: tablet gaming control
Number of subjects: 18
Study 28532408 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) administered at 2 days and 1 year postoperatively
Number of subjects: 60
Study 28532408 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline only)
Number of subjects: 60
Study 25398399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous thoracic paravertebral block (USG-PVB)
Number of subjects: 90
Study 25398399 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural block (TEB) with fentanyl and ropivacaine
Number of subjects: 90
Study 22538838 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time sick leave
Number of subjects: 171
Study 22538838 — intervention group
Group type: COMPARATOR
Intervention: Full-time sick leave
Number of subjects: 171
Study 21219551 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate and Mefloquine (fixed dose combination)
Number of subjects: 50
Study 21219551 — intervention group
Group type: COMPARATOR
Intervention: Artesunate and Mefloquine (loose tablets)
Number of subjects: 50
Study 18466266 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tadalafil
Number of subjects: 406
Study 18466266 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tadalafil
Number of subjects: 406
Study 18466266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 16484450 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 0
Study 16484450 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin treatment
Number of subjects: 0
Study 16484450 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of observational and clinical trial data
Number of subjects: 0
Study 12622770 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine, 20 mg/day
Number of subjects: 16
Study 12622770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11421880 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole group (20 mg b.d. for 7 days + 14 days additional therapy with omeprazole 20 mg)
Number of subjects: 77
Study 11421880 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (7 days triple therapy + placebo for 14 days)
Number of subjects: 77
Study 9408724 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent practices
Number of subjects: 0
Study 7970505 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 160 mg/day
Number of subjects: 342
Study 7970505 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg/day
Number of subjects: 342
Study 7970505 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/day
Number of subjects: 342
Study 7970505 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 1280 mg/day
Number of subjects: 342
Study 3302193 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (retinyl palmitate 2000 IU)
Number of subjects: 40
Study 3302193 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution (control)
Number of subjects: 40
Study 31424173 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxgraft
Number of subjects: 20
Study 31424173 — intervention group
Group type: COMPARATOR
Intervention: Puros
Number of subjects: 20
Study 29096949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control management (using clinical symptoms and biomarkers)
Number of subjects: 244
Study 29096949 — intervention group
Group type: COMPARATOR
Intervention: Clinical management algorithm (symptom-driven decisions)
Number of subjects: 244